Sagimet Biosciences announced the appointments of Tim Walbert and Paul Hoelscher to the board of directors of the Company, effective April 1, 2024. Walbert has nearly 30 years of biotechnology and industry experience. He joins Sagimet’s board following a 15-year tenure as president, CEO, and chairman of the board at Horizon Therapeutics. Hoelscher served as executive vice president and CFO of Horizon Therapeutics from 2014 to 2022, prior to the company’s acquisition by Amgen. Sagimet also announced that Jinzi Wu, Ph.D. and Rick Rodgers notified the Board that they will not stand for re-election at the upcoming 2024 annual meeting of stockholders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Sagimet Biosciences Announces Board Expansion and Director Changes
- Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- Sagimet Biosciences price target lowered to $46 from $47 at JMP Securities
